WALTHAM, Mass.--(BUSINESS WIRE)--NeuroMetrix, Inc. (Nasdaq: NURO, NUROW) announced today that it plans to
issue its 2016 third quarter financial results before the opening of the
market on Thursday, October 20, 2016. The Company will host a conference
call at 8:00 a.m., Eastern Time on October 20, 2016 to discuss its
financial results as well as business developments affecting the Company.

The conference call may be accessed in the United States by dialing
844-787-0799 and using the confirmation code 89762513. Internationally,
the conference call may be accessed by dialing 661-378-9630 and using
the same confirmation code. The earnings press release and accompanying
condensed financial statements will be accessible from the Company's
website at www.NeuroMetrix.com under
the "Investor Relations" tab.

A replay of the conference call will be available starting two hours
after the call by dialing 855-859-2056, domestically and 404-537-3406,
internationally. The confirmation code to access the replay is 89762513.
The replay will be available for one week after the conference call.

About NeuroMetrix

NeuroMetrix is a commercial stage, innovation driven healthcare company
combining bioelectrical and digital medicine to address chronic health
conditions including chronic pain, sleep disorders, and diabetes. The
company's lead product is Quell®, an over-the-counter
wearable therapeutic device for chronic pain. Quell is integrated into a
digital health platform that helps patients optimize their therapy and
decrease the impact of chronic pain on their quality of life. The
company also markets DPNCheck®, a rapid point-of-care test
for diabetic neuropathy, which is the most common long-term complication
of Type 2 diabetes. The company maintains an active research effort and
has several pipeline programs, including a therapeutic device for
restless leg syndrome. The company is located in Waltham,
Massachusetts and was founded as a spinoff from the Harvard-MIT Division
of Health Sciences and Technology in 1996. For more information, please
visit www.NeuroMetrix.com.